Accretion Pharmaceuticals IPO: A Pill of Opportunity Opens May 14, 2025
📅 Mark your trading calendars and hide your panic pills — Accretion Pharmaceuticals is heading to the NSE Emerge platform on May 14, 2025. And no, this isn’t one of those bitter pills to swallow. In fact, the company just turned a ₹0.1 crore net profit into ₹3.9 crore in one year — a jump so steep it should come with a health warning.
💉 What is Accretion Pharmaceuticals?
Based in Gujarat, Accretion Pharmaceuticals is the company your doctor won’t prescribe but your broker just might. It manufactures pharmaceutical formulations like tablets, capsules, oral liquids, and ointments, mostly for other companies under loan licensing and contract manufacturing.
In simple terms, it’s the ghostwriter of pharma—writing blockbusters without taking credit. But now, with its ₹29.75 crore IPO, it’s stepping into the spotlight to say, “Doctor investor, I’m ready for your examination.”
💰 IPO Details (For Those Who Like Their Drugs in Dosage Form)
Source table
IPO Detail
Data
Issue Size
₹29.75 crore
Price Band
₹96 – ₹101
Lot Size
1,200 shares
Minimum Investment
₹1,21,200 (Yes, you’ll need a healthy bank account)
Issue Opens
May 14, 2025
Issue Closes
May 16, 2025
Allotment Date
May 19, 2025
Listing Date
May 21, 2025
Listing Exchange
NSE Emerge
📊 The Financial X-ray Report
Accretion Pharmaceuticals may be small, but its 2024 financials suggest it’s no placebo.
🧾 Income Statement (₹ crore)
Source table
Indicator
FY24
FY23
FY22
Total Revenue
33.9
29.5
22.6
Total Expenses
28.2
29.4
22.5
PBT (Profit Before Tax)
5.8
0.1
0.1
Tax
1.9
0
0
Net Profit
3.9
0.1
0.1
NPM %
11.51%
0.35%
0.35%
EPS (Adjusted)
₹3.5
₹0.1
₹0.1
📈 Observations:
Revenue grew by ~15% YoY, but net profit grew by 3,800% — someone give the finance team a standing ovation and possibly a raise.
Net Profit Margins exploded from 0.35% to 11.5%. That’s
